J Korean Breast Cancer Soc.  2002 Jun;5(2):108-112. 10.4048/jkbcs.2002.5.2.108.

Imaging of Estrogen Receptors with Iodine-123- Iabeled Estradiol in Primary Breast Cancer Patients

• Park KI
• Noh WC
• Lee RA
• Choi CW
• Bang HY
• Hwang DY
• Choi DW
• Lee JI
• Paik NS
• Moon NM

• KMID: 2173557
• DOI: http://doi.org/10.4048/jkbcs.2002.5.2.108

Abstract

PURPOSE: We evaluated the feasibility of non-invasive imaging of estrogen receptors (ER) in primary breast cancer with iodine-123-labeled ER specific ligand (17alpha,20E)-21-[123I] iodo-19-nonpregna-1,3,5-(10), 20-tetraene-3, 17-diol using conventional nuclear medicine technique.
METHODS
Before they underwent surgical management, planar scintigraphy and single-photon emission computed tomography (SPECT) were performed in 18 patients with proven primary breast cancer, after single IV injection of 5~10 mCi I-123-estradiol. The results were compared with those of immunohistochemical staining against ER of the surgical specimens.
RESULTS
Planar and SPECT imaging showed hot uptake in nine of eighteen (50%) breast cancer patients. The results of ER immunohistochemistry were all positive in these patients. In the 9 cases of negative scintigraphy, 8 showed negative staining results but one showed positive staining results. Therefore, the overall concordance rate of ER scintigraphy and ER immunohistochemistry was 94.4% (17/18).
CONCLUSION
ER scintigraphy using I-123-estradiol is a highly predictable in vivo technique to detect ER-positive breast cancer preoperatively. It has potential application as a re-liable diagnostic modality and indicator of hormone therapy for breast cancer patients.

Keyword

Breast cancer; Estrogen receptor; Scintigraphy

MeSH Terms

Breast Neoplasms*
Breast*
Estradiol*
Estrogens*
Humans
Immunohistochemistry
Negative Staining
Nuclear Medicine
Radionuclide Imaging
Receptors, Estrogen*
Tomography, Emission-Computed
Tomography, Emission-Computed, Single-Photon
Estradiol
Estrogens
Receptors, Estrogen